Beam Therapeutics (BEAM) Common Equity (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Common Equity data on file, last reported at $1.2 billion in Q1 2026.

• Common Equity for Q1 2026 came in at $1.2 billion, up 3.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 3.1% YoY), and the FY2025 annual result was $1.2 billion, up 68.82% from the prior year.
• Common Equity fell to $1.2 billion in Q1 2026 per BEAM's latest filing, from $1.2 billion in the prior quarter.
• Over five years, Common Equity peaked at $1.2 billion in Q4 2025 and troughed at $714.5 million in Q3 2022.
• A 5-year average of $896.9 million and a median of $829.1 million in 2022 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2024: Common Equity jumped 96.26% in 2022, then decreased 25.25% in 2024.
• A 5-year view of Common Equity shows it stood at $733.5 million in 2022, then jumped by 33.79% to $981.3 million in 2023, then declined by 25.25% to $733.5 million in 2024, then surged by 68.82% to $1.2 billion in 2025, then dropped by 5.97% to $1.2 billion in 2026.
• Business Quant data shows BEAM's Common Equity at $1.2 billion in Q1 2026, $1.2 billion in Q4 2025, and $966.0 million in Q3 2025.